Skip to main content
recep.adiyaman
Vision About Experience Education Skills Publications Tools Newsletter Updates Podcasts Blog Contact CV Subscribe
All Issues
Older Newer
Daily Signal May 06, 2026 · 9 min read

Issue #102: Advances in Molecular Docking Methodologies

Protein Design Digest #102: Advances in Molecular Docking Methodologies

Share X LinkedIn
Protein Design Daily

Building something in Protein Design?

I love collaborating on new challenges. Let's build together.

LinkedIn Email

Subscribe to Protein Design Digest

Daily curated signals from arXiv, PubMed, and BioRxiv.

Signal of the Day

Advances in Molecular Docking Methodologies

Computer-aided drug design (CADD) is undergoing a fundamental paradigm shift driven by the transition from classical biophysical methods to deep learning architectures and generative artificial intelligence. This review analyzes the evolution of molecular docking algorithms. We examine traditional programs (AutoDock Vina, Glide, GOLD) based on stochastic conformational search and empirical scoring functions, which retain the status of gold standard due to the high physical validity of the generated predictions. Software solutions for high-throughput virtual screening, such as distributed pipelines like EasyDock and graphical interfaces like EasyDockVina, are analyzed. Particular attention is paid to the latest generative AI models (DiffDock, GNINA, AlphaFold 3, DynamicBind, FABFlex), which address the computational challenges of blind docking and macromolecular receptor flexibility. We assess the systemic crisis of neural network generalization ability identified in independent benchmarks (PoseBusters, Bento, NextTopDocker) and substantiate the need to integrate the laws of molecular physics into the latent spaces of models. We conclude that the formation of hybrid pipelines, combining the speed of AI with the rigor of classical mechanics, is a necessary development.

Why this matters: Expands the searchable sequence space for novel folds and high-affinity binders.

Also Worth Reading

Do Larger Models Really Win in Drug Discovery? A Benchmark Assessment of Model Scaling in AI-Driven Molecular Property and Activity Prediction

The rapid growth of molecular foundation models and general-purpose large language models has encouraged a scale-centric view of artificial intelligence in drug discovery, in which larger pretrained models are expected to supersede compact cheminformatics models and task-specific graph neural networks (GNNs). We test this assumption on 22 molecular property and activity endpoints, including public ADMET and Tox21 benchmarks and two internal anti-infective activity datasets. Across 167,056 held-out task–molecule evaluations under structure-similarity-separated five-fold cross-validation (37,756 ADMET, 77,946 Tox21, 49,266 anti-TB and 2,088 antimalaria), classical machine-learning (ML) models such as RF(ECFP4) and ExtraTrees(RDKit descriptors) win ten primary-metric tasks, GNNs such as GIN and Ligandformer win nine, and pretrained molecular sequence models such as MoLFormer and ChemBERTa2 win three. Rule-based SAR reasoning baselines, represented by GPT5.5-SAR and Opus4.7-SAR, do not win under the prespecified primary metrics, although train-fold-derived SAR knowledge provides measurable but uneven gains for SAR reasoning and interpretation. These results indicate that compact, specialized models remain highly effective for molecular property and activity prediction. The performance differences among classical ML, GNN and pretrained sequence models are often modest and endpoint-dependent, whereas larger or more general models do not provide a universal predictive advantage. Large models may still add value for zero-shot reasoning, SAR interpretation and hypothesis generation, but the results suggest that predictive performance depends on the alignment among molecular representation, inductive bias, data regime, endpoint biology and validation protocol.

Identification of paucinervin D as a natural sphingosine-1-phosphate receptor 1 agonist: Insights from pharmacophore modeling, docking, molecular dynamics simulations, and density functional theory.

Sphingosine-1-phosphate receptor 1 (S1PR1), a member of the G protein-coupled receptor (GPCR) family, is a crucial therapeutic target for various diseases. Activation of S1PR1 has been recognized as an effective therapeutic strategy for multiple sclerosis (MS), inflammatory bowel disease (IBD), and psoriasis. Natural products (NPs) serve as a rich source of bioactive compounds for drug discovery. Here, we aimed to discover novel S1PR1 agonists from NPs via multi-level virtual screening (VS). Using a validated HipHop pharmacophore model, we screened a database containing 54,642 NPs, followed by molecular docking. Based on binding mode analysis, four candidate S1PR1 agonists (NPC323626, NPC264112, NPC469907, and NPC22192) were selected. Subsequent molecular dynamics (MD) simulations and binding free energy calculations confirmed the stability of the receptor-ligand complexes and their binding affinities. Among the four candidates, NPC469907 exhibited the strongest binding affinity for S1PR1, with a value of -58.08 ± 0.13 kJ/mol. Furthermore, hydrogen bonds formed between NPC469907 and Glu121 of S1PR1 were found to be essential for receptor activation. Quantum mechanical calculations further revealed that the phenyl-ring-attached hydrogen site in NPC469907 could be modified without compromising its ability to activate S1PR1. The analysis of Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) indicated that NPC469907 possessed favorable pharmacokinetic properties and low toxicity. In conclusion, our study identified NPC469907 as a promising natural S1PR1 agonist and established an effective VS strategy for the discovery of novel S1PR1 agonists.

Mechanisms Underlying the Therapeutic Effects of GeXiaZhuYu Decoction Treating Colorectal Cancer based on Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulations.

GeXiaZhuYu Decoction (GXZYD) has long been used in the context of Colorectal Cancer (CRC), yet its active constituents and associated molecular features remain incompletely characterized at the systems level. An integrative computational strategy combining network pharmacology, molecular docking, Molecular Dynamics (MD) simulations, and MM-GBSA binding free-energy analysis was applied to characterize the potential pharmacological landscape of GXZYD in CRC. Active compounds and predicted targets were collected from multiple databases, and CRC-related genes were integrated from GeneCards, OMIM, TTD and DrugBank. Overlapping targets were analyzed by PPI networks and GO/KEGG enrichment analyses. MD simulations and MMGBSA calculations were performed to evaluate the dynamic and energetic characteristics of representative ligand-protein associations. Single-cell RNA-seq data (GSE144735) were analyzed to determine cell-type-specific expression of key targets. Quercetin, luteolin, and kaempferol were identified as representative flavonoid constituents of GXZYD, while HSP90AA1, AKT1, and TP53 were highlighted as network-prioritized targets. Molecular docking suggested favorable binding tendencies between these flavonoids and the selected targets. MD simulations revealed target-dependent dynamic behaviors, with HSP90AA1-associated complexes showing comparatively smaller structural fluctuations, AKT1- associated complexes exhibiting moderate stability, and TP53-associated complexes displaying larger conformational variability consistent with its intrinsic flexibility. MM-GBSA analysis supported relatively favorable binding free-energy trends for flavonoids interacting with HSP90AA1 among the examined targets. Single-cell analysis indicated that HSP90AA1 shows relatively higher expression in epithelial cell populations compared with AKT1 and TP53. These computational findings provide a systems-level and structure-informed perspective on the potential molecular associations of GXZYD constituents with CRC-related targets, while not implying direct pharmacological effects or causal mechanisms. This study delineates representative active constituents, network-prioritized targets, and pathway-level associations related to GXZYD in colorectal cancer, offering testable hypotheses and a theoretical framework for future experimental validation.

Research & AI Updates

From the Industry

Quick Reads

In Vitro antileishmanial evaluation, molecular docking, dynamics simulations, and DFT Studies of tetrahydropyridine derivatives as potential trypanothione reductase inhibitors.

Leishmaniasis, a neglected tropical disease caused by Leishmania parasites, lacks safe and effective treatments due to drug resistance and toxicity. Read more →

Synthesis, Characterization and Biological Evaluation of New Furo[2,3-b] pyridine Derivative: Molecular Docking, Antioxidant and Antimicrobial Activity Enhanced by Silver Nanoparticle Formulation.

Pyridine-based derivatives are well-known for their broad-spectrum therapeutic applications, particularly as antimicrobial and antioxidant agents. Read more →

Identification of PPIA, DPP4, and ITK as Potential Targets of Pterostilbene in Abdominal Aortic Aneurysm: A Network Pharmacology and Molecular Docking Study.

Pterostilbene is a polyphenolic compound with antioxidant and anti-inflammatory properties. Read more →

Mechanistic Investigation of Wenfei Huaxian Decoction in the Treatment of Pulmonary Fibrosis Based on UPLC/Q-TOF-MS/MS, Network Pharmacology, Experimental Validation, and Molecular Docking.

Idiopathic pulmonary fibrosis (IPF) is increasing and poses a major health threat. Read more →

Novel 1,2,3-triazole-thiophene hybrids: synthesis, anti-MRSA/MSSA activity, antioxidant potential, and acetylcholinesterase ınhibition supported by molecular docking.

The discovery of single-molecule therapeutics capable of simultaneously addressing antibiotic resistance and neurodegeneration represents a critical unmet need in modern medicinal chemistry. Read more →

Network Pharmacology and Molecular Docking Analysis on the Mechanism of Hedyotis Diffusa in Overcoming Resistance in EGFR Mutant Cell Line HCC827-GR and Its Experimental Verification.

Hedyotis diffusa is a Chinese herbal medicine commonly used to treat various forms of inflammation and tumors. Read more →

Novel green synthesis of polyfunctionally substituted phthalazines promoted by visible light, DFT studies and molecular docking with antimicrobial and antibiofilm potency.

Visible-Light-Mediated synthesis is a green and efficient technique that has garnered interest from organic chemists. Read more →

Discovery of compound candidates for the treatment of allergic diseases: integration of DFT analyses, molecular docking, molecular dynamics simulations, and ADMET profiling.

Pipeline Tip

Always validate pLDDT scores before using AlphaFold models for docking.

Resources & Tools

The protein structure is the language of life; design is its poetry. — Recep Adiyaman

BS HF DK